19 results
424B5
ZYME
Zymeworks Inc.
3 May 24
Prospectus supplement for primary offering
4:17pm
and Affordable Care Act, or the PPACA, authorized the FDA to approve similar versions of innovative biologics, commonly known as biosimilars. Under
424B5
ZYME
Zymeworks Inc.
3 May 24
Prospectus supplement for primary offering
4:11pm
is included in the 2010 Patient Protection and Affordable Care Act, or the PPACA, authorized the FDA to approve similar versions of innovative biologics
8-K
EX-99.1
ZYME
Zymeworks Inc.
2 May 24
Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results
4:07pm
to enter multiple Phase 1 trials in the coming 24 months, our commitment to advancing innovative solutions remains evident, with more preclinical data
8-K
EX-99.1
ZYME
Zymeworks Inc.
28 Mar 24
Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors
4:16pm
with difficult-to-treat cancers and other serious diseases is evident in their innovative approach in developing next-generation product candidates. I am
8-K
EX-10.1
vhwekfsxu2m 0p
16 May 23
Entry into a Material Definitive Agreement
8:30am
424B5
avx0zj
8 May 23
Prospectus supplement for primary offering
5:19pm
424B5
hhp6pnoy7nf9pab
8 May 23
Prospectus supplement for primary offering
5:18pm
8-K
EX-99.1
0l5sy0
21 Dec 22
Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab
8:37am
DEF 14A
h21melzpso zok
25 Nov 22
Definitive proxy
6:16am
424B5
ygx3pra
9 Nov 22
Prospectus supplement for primary offering
4:29pm
10-Q
hi88brrhw3fobqt
8 Nov 22
Quarterly report
4:09pm
424B5
npv9d8tk8fjbp0wl
21 Oct 22
Prospectus supplement for primary offering
4:16pm
8-K
EX-99.1
pxel1c2unw4e 7596
19 Oct 22
Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody
6:26am
424B5
ol2ea4 ln
13 Oct 22
Prospectus supplement for primary offering
4:56pm
- Prev
- 1
- Next